Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

Despite the slightly warmer weather and longer periods of sunshine, we are still in the depths of cold and flu season, a ...

“My son’s lips, at this point, started to turn blue. He also had a febrile seizure, which is why his body was stiff and ...

RSV is a common virus that affects the lungs and breathing passages, and here are some steps you can take to protect yourself ...

Weekly case counts for the two respiratory illnesses have spiked in Erie County since Christmas, rising from a few dozen each in late December to 268 RSV cases and 321 flu cases the week ending Jan.

It is a potentially fatal virus that can lead to hospitalisations and death in infants, but also in elderly and chronically ill adults. Two RSV vaccines were approved for use in Australia last ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.